ALX Oncology ALXO
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of ALX Oncology (ALXO)
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Key Insights
Critical company metrics and information
Latest Closing Price
$1.06Market Cap
$56.59 MillionPrice-Earnings Ratio
-0.41Total Outstanding Shares
52.74 Million SharesTotal Employees
80Dividend
No dividendIPO Date
July 17, 2020SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
323 allerton avenue, South san francisco, CA, 94080Homepage
https://www.alxoncology.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $86.26 Million |
| Net Cash Flow, Continuing | $-4.84 Million |
| Net Cash Flow From Financing Activities | $30.82 Million |
| Net Cash Flow From Operating Activities, Continuing | $-121.91 Million |
| Net Cash Flow From Investing Activities, Continuing | $86.26 Million |
| Net Cash Flow From Operating Activities | $-121.91 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Interest Expense, Operating | $1.73 Million |
| Depreciation and Amortization | $900,000 |
| Other Operating Expenses | $25.19 Million |
| Research and Development | $116.37 Million |
| Income/Loss From Continuing Operations Before Tax | $-134.85 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-134.85 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $19,000 |
| Comprehensive Income/Loss Attributable To Parent | $-134.83 Million |
| Comprehensive Income/Loss | $-134.83 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Noncontrolling Interest | $0 |
| Liabilities And Equity | $147.78 Million |
| Other Non-current Liabilities | $5.06 Million |
| Other Non-current Assets | $10.52 Million |
| Noncurrent Liabilities | $15.66 Million |
| Liabilities | $34.16 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ALXO from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.